1-3 of 3
Phillip Scheinberg
Close
Sort by
Journal Articles

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Clinical Trials & Observations
Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E. Brammer, Tatyana A. Feldman, Marcelo Capra, Elizabeth A. Brem, Santosh Nair, Phillip Scheinberg, Juliana Pereira, Leyla Shune, Erel Joffe, Patricia Young, Susan Spruill, Afton Katkov, Robert McRae, Ivor Royston, Douglas V. Faller, Lisa Rojkjaer, Pierluigi Porcu
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6339–6350.
https://doi.org/10.1182/bloodadvances.2023010330
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumab

Clinical Trials & Observations
Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R. Parikh, Aarthi Shenoy, Julie Thompson, Barbara Weinstein, Phillip Scheinberg, A. John Barrett, Ronan Desmond, Neal S. Young, Christopher S. Hourigan
Journal: Blood Advances
Blood Adv (2019) 3 (7): 980–983.
https://doi.org/10.1182/bloodadvances.2018030411
Published: 2019
Includes: Supplemental data
Journal Articles

Activity of eltrombopag in severe aplastic anemia

Clinical Trials & Observations
Phillip Scheinberg
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3054–3062.
https://doi.org/10.1182/bloodadvances.2018020248
Published: 2018